Product Name: Huperzine A
Test Method: HPLC
Specifications: Huperzine A 1%  5%  98%  by HPLC
Molecular Formula: C15H18N2O
Molecular Mass: 242.316
CAS No.: 120786-18-7
 Huperzine A has been proven superior to drugs licensed for the treatment of Alzheimer's, including the leading anticholine sterase drugs physostigmine and tacrine. Huperzine A improved learning and memory in mice better than tacrine. Unlike physostigmine and tacrine, Huperzine A acts specifically on AchE in the brain rather than AchE found elsewhere in the body i.e., far less is wasted on irrelevant effects. 
Unlike physostigmine and tacrine, Huperzine A does not appear to bind to receptors in the central nervous system, which can cause adverse side effects. Its effects last 10 to 12 times longer than physostigmine and tacrine (up to 8 hours).
1) Huperzine A can improve memory, thinking, and behavioral function in people with
   Alzheimer's disease, multi-infarct dementia, and senile dementia, and increase
   the level of the neurotransmitter acetylcholine by blocking its breakdown.
 
2) It may also protect neurons from cell death caused by toxic levels of glutamate
    and protect against some of the effects of chemical nerve agents used in warfare,
    such as soman.
3) It is also the treatment of AD in a randomized controlled trial of its effect
    on cognitive function.
 
Application 
Huperzine A has potent pharmacological effects and, particularly since long-term safety has not been determined, it should only be used with medical supervision. It may have some effectiveness in Alzheimer's disease and age-related memory impairment. It has been used to treat fever and some inflammatory disorders, but there is no credible scientific evidence to support these uses.